STOCK TITAN

Lisata Therapeutics (LSTA) Financials

LSTA NASDAQ
Trailing 12 months to September 30, 2026
Revenue $100K -90.7% YoY
Net Income -$17.2M n/m YoY
EPS (Diluted) -$1.88 n/m YoY
Free Cash Flow -$21.7M n/m YoY
Market Cap $9.8M as of Nov 19, 2026
Price / Sales 98.3x on $100K revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 1.3x on $7.6M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 19, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the LSTA SEC filings page.

Lisata Therapeutics, Inc. (LSTA) reported $100K in revenue over the twelve months to Sep 30, 2026, down 90.7% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LSTA FY2025

Lisata remains development-stage: 2025 revenue was only $170K while operating costs stayed far above commercial sales.

The near match between the 2025 net loss of $16.6M and operating cash flow of -$15.9M indicates that reported losses are translating into cash use rather than being mainly non-cash accounting charges. Free cash flow of -$16.0M was nearly identical, so capital spending was not the main source of the cash reduction.

Cost reductions did not create operating leverage: R&D fell 29.9% from FY2024 while revenue fell 83.0%, leaving sales tiny relative to the development cost base. SG&A still totaled $10.4M, or 6135.3% of revenue, showing the organization remains built for development rather than commercial volume.

The balance sheet contracted alongside the business: total assets fell 49.3% from FY2024 to FY2025, while liabilities fell 44.7%. That left liabilities at 17.7% of assets versus 16.2% previously, while the current ratio narrowed from 6.2x to 5.8x—less short-term cushion in relative terms despite current assets still exceeding current liabilities.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Lisata Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Altman Z-Score Distress
-45.06

Lisata Therapeutics, Inc. scores -45.06, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $564.7M against total assets of $17.7M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
1/7

Lisata Therapeutics, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality No Cash Backing
N/A

Lisata Therapeutics, Inc. reported a net loss of $16.6M while operations used $15.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$0
YoYn/m
QoQn/m

Lisata Therapeutics, Inc. generated $0 in revenue in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EBITDA
-$10.0M
YoYn/m
QoQn/m
5Y CAGRn/m

Lisata Therapeutics, Inc.'s EBITDA was -$10.0M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$6.8M
YoYn/m
QoQn/m
5Y CAGRn/m

Lisata Therapeutics, Inc. reported a net loss of $6.8M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.73
YoYn/m
QoQn/m

Lisata Therapeutics, Inc. earned -$0.73 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$12.7M
YoYn/m
QoQn/m

Lisata Therapeutics, Inc. recorded an outflow of $12.7M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$282.7M
YoY+1388.1%
QoQ+2607.2%
5Y CAGR+85.8%
10Y CAGR+31.3%

Lisata Therapeutics, Inc. held $282.7M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
11M
YoY+22.5%
QoQ+19.9%

Lisata Therapeutics, Inc. had 11M shares outstanding in Q3 2026. This represents an increase of 22.5% from the same quarter a year earlier. Against the prior quarter it is up 19.9%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-88.8%
YoY-64.3pp
QoQ-53.3pp
5Y change-81.8pp

Lisata Therapeutics, Inc.'s quarterly ROE was -88.8% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 64.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 53.3 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$5.2M
YoY+165.7%
QoQ+791.4%
5Y CAGR+4.8%

Lisata Therapeutics, Inc. invested $5.2M in research and development in Q3 2026. This represents an increase of 165.7% from the same quarter a year earlier. Against the prior quarter it is up 791.4%.

Capital Expenditures
$0
YoYn/m
QoQn/m

Lisata Therapeutics, Inc. reported no capital expenditure in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Share Buybacks

Not reported for Q3 2026.

LSTA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LSTA quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$0n/m$0-100.0%$0n/m$100K-90.0%$0n/m$70Kn/m$0n/m$1.0Mn/m
R&D Expenses$5.2M+165.7%$584K-74.1%$1.2M-53.7%$1.1M-61.5%$2.0M-22.9%$2.3M-13.4%$2.6M-19.7%$3.0M-2.1%
SG&A Expenses$4.8M+96.5%$3.4M+26.9%$3.7M+15.2%$2.0M$2.5M-12.1%$2.7M-8.1%$3.2M-3.4%N/A
Operating Income-$10.0Mn/m-$4.0Mn/m-$4.9Mn/m-$3.1Mn/m-$4.4Mn/m-$4.9Mn/m-$5.8Mn/m-$4.9Mn/m
EBITDA-$10.0Mn/m-$4.0Mn/m-$4.9Mn/m-$3.1Mn/m-$4.4Mn/m-$4.8Mn/m-$5.8Mn/m-$4.9Mn/m
Income Tax-$6.0Mn/m$0n/m-$387Kn/m$0n/m$0n/m$0n/m-$962Kn/m$0n/m
Net Income-$6.8Mn/m-$2.9Mn/m-$4.5Mn/m-$3.0Mn/m-$4.2Mn/m-$4.7Mn/m-$4.7Mn/m-$4.6Mn/m
EPS (Basic)-$0.73n/m-$0.32n/m-$0.50n/m-$0.33n/m-$0.49n/m-$0.54n/m-$0.55n/m-$0.55n/m
EPS (Diluted)-$0.73n/m-$0.32n/m-$0.50n/m-$0.33n/m-$0.49n/m-$0.54n/m-$0.55n/m-$0.55n/m
Diluted Shares (Avg)9M+6.5%9M+5.8%9M+4.7%N/A9M+5.0%9M+3.6%9M+3.7%N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

LSTA Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LSTA quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$648.4M+2880.0%$11.0M-56.2%$14.1M-51.5%$17.7M-49.3%$21.8M-43.0%$25.2M-40.9%$29.0M-39.9%$35.0M-36.0%
Current Assets$287.8M+1233.7%$11.0M-55.7%$14.0M-51.0%$17.7M-48.8%$21.6M-42.8%$24.9M-40.7%$28.6M-39.8%$34.6M-35.9%
Cash & Equivalents$282.7M+1388.1%$10.4M-38.0%$13.1M-35.4%$16.0M-1.6%$19.0M-2.6%$16.8M-40.5%$20.2M-7.3%$16.2M-28.3%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Accounts ReceivableN/AN/AN/A$0-100.0%$502K$501K$750K$900Kn/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Goodwill$64.7MN/AN/A$0N/AN/AN/AN/A
Total Liabilities$640.8M+13709.6%$3.0M-30.7%$3.4M-12.7%$3.1M-44.7%$4.6M-2.6%$4.4M-4.2%$3.9M-29.4%$5.7M-16.4%
Current Liabilities$20.4M+347.0%$3.0M-30.7%$3.3M-12.9%$3.1M-45.3%$4.6M-2.6%$4.3M-3.2%$3.8M-28.6%$5.6M-14.8%
Non-Current Liabilities$620.4M+861497.2%$50K-30.6%$72K0.0%$72K0.0%$72K0.0%$72K-39.5%$72K-56.1%$72K-65.7%
Total Equity$7.6M-56.0%$8.2M-60.8%$10.9M-56.9%$14.9M-49.8%$17.4M-48.4%$21.0M-45.0%$25.4M-41.0%$29.6M-38.6%
Retained Earnings-$578.9Mn/m-$572.1Mn/m-$569.1Mn/m-$564.7Mn/m-$561.7Mn/m-$557.4Mn/m-$552.8Mn/m-$548.1Mn/m

Not reported in any period shown, so not listed: Inventory, Long-Term Debt.

LSTA Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LSTA quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$12.7Mn/m-$2.6Mn/m-$3.1Mn/m-$3.2Mn/m-$3.3Mn/m-$4.0Mn/m-$5.4Mn/m-$4.5Mn/m
Depreciation & Amortization$3K-93.2%$3K-93.2%$2K-95.3%$15K-63.4%$44K+4.8%$44K-2.2%$43K-6.5%$41K-12.8%
Stock-Based Compensation$58K-75.0%$214K-10.5%$364K-31.3%N/A$232K-29.1%$239K+0.8%$530K+16.7%N/A
Capital Expenditures$0n/m$0n/m$0-100.0%$0n/m$0n/m$0n/m$28Kn/m$0n/m
Free Cash Flow-$12.7Mn/m-$2.6Mn/m-$3.1Mn/m-$3.2Mn/m-$3.3Mn/m-$4.0Mn/m-$5.4Mn/m-$4.5Mn/m
Investing Cash Flow$72.9M+1315.9%$0-100.0%$0-100.0%$0-100.0%$5.2Mn/m$505K-95.7%$9.4M+46.5%$1.4Mn/m
Financing Cash Flow$212.1M+59974.5%$29K-54.7%$181Kn/m$205Kn/m$353Kn/m$64K+100.0%-$23Kn/m-$96K-500.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

LSTA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

LSTA quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating MarginN/AN/AN/A-3080.0%N/A-6954.3%N/A-494.9%
Net MarginN/AN/AN/A-2954.0%N/A-6655.7%N/A-461.0%
Return on Equity-88.8%-64.3pp-35.5%-13.4pp-41.1%-22.5pp-19.9%-4.3pp-24.5%-9.8pp-22.2%-9.0pp-18.6%-6.1pp-15.6%-4.5pp
Return on Assets-1.1%+18.5pp-26.6%-8.0pp-31.9%-15.6pp-16.7%-3.5pp-19.5%-6.6pp-18.5%-6.7pp-16.3%-5.1pp-13.2%-3.4pp
Current Ratio14.09+9.4x3.69-2.1x4.23-3.3x5.76-0.4x4.72-3.3x5.77-3.6x7.52-1.4x6.16-2.0x
Liabilities-to-Equity83.84+83.6x0.37+0.2x0.31+0.2x0.210.0x0.27+0.1x0.21+0.1x0.150.0x0.19+0.1x
Asset Turnover0.000.0x0.000.0x0.000.0x0.010.0x0.000.0x0.000.0x0.000.0x0.030.0x
FCF MarginN/AN/AN/A-3249.0%N/A-5651.4%N/A-452.8%

Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Lisata Therapeutics, Inc. LSTA FY2025 $170K -$16.6M N/A $9.8M —
Allarity Therapeutics, Inc. ALLR FY2025 $320K -$11.2M N/A $13.8M —
Bolt Biotherapeutics, Inc. BOLT FY2025 $7.7M -$33.4M N/A $13.2M 58/100
Seres Therapeutics, Inc. MCRB FY2025 $789K $5.7M N/A $13.6M —
BioCardia, Inc. BCDA FY2025 $0 -$8.2M N/A $11.7M —
Fractyl Health, Inc. GUTS FY2025 $0 -$141.0M N/A $12.7M —

Frequently Asked Questions

Lisata Therapeutics, Inc. (LSTA) reported $170K in total revenue for fiscal year 2025. This represents a -83.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Lisata Therapeutics, Inc. (LSTA) revenue declined by 83.0% year-over-year, from $1.0M to $170K in fiscal year 2025.

No, Lisata Therapeutics, Inc. (LSTA) reported a net loss of $17.2M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $16.6M.

Lisata Therapeutics, Inc. (LSTA) reported diluted earnings per share of -$1.91 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lisata Therapeutics, Inc. (LSTA) had EBITDA of -$18.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Lisata Therapeutics, Inc. (LSTA) has a return on equity of -111.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Lisata Therapeutics, Inc. (LSTA) recorded an outflow of $16.0M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Lisata Therapeutics, Inc. (LSTA) recorded an outflow of $15.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Lisata Therapeutics, Inc. (LSTA) had $17.7M in total assets as of fiscal year 2025, including both current and long-term assets.

Lisata Therapeutics, Inc. (LSTA) invested $28K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Lisata Therapeutics, Inc. (LSTA) invested $7.9M in research and development during fiscal year 2025.

Lisata Therapeutics, Inc. (LSTA) had 9M shares outstanding as of fiscal year 2025.

Lisata Therapeutics, Inc. (LSTA) had a current ratio of 5.76 as of fiscal year 2025, which is generally considered healthy.

Lisata Therapeutics, Inc. (LSTA) had a liabilities-to-equity ratio of 0.21 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Lisata Therapeutics, Inc. (LSTA) had a return on assets of -93.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Lisata Therapeutics, Inc. (LSTA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $9.8M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Lisata Therapeutics, Inc. (LSTA) trades at 98.3x sales, its market capitalization divided by $100K revenue, trailing 12 months to September 30, 2026. The market capitalization is $9.8M as of Nov 19, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Lisata Therapeutics, Inc. (LSTA) held $16.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $15.9M over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Lisata Therapeutics, Inc. (LSTA) has an Altman Z-Score of -45.06, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Lisata Therapeutics, Inc. (LSTA) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Lisata Therapeutics, Inc. (LSTA) reported a net loss of $16.6M while operations used $15.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top